Analysis of effect of mosapride citrate administration on increasing in type 2 diabetic patient's postprandial plasma active glucagon-like peptide-1
Not Applicable
- Conditions
- Type 2 diabetes
- Registration Number
- JPRN-UMIN000016861
- Lead Sponsor
- Chiba University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 16
Inclusion Criteria
Not provided
Exclusion Criteria
1) Type 1 diabetic patients 2) Patient with a history of diabetic coma within 6 months 3) Necessity of insulin such as severe infection, perioperative period, and severe external injury 4) Severe hepatic and renal disorder (Ccr < 30mL/min, serum Cre > 2.0 mg/dl (female), 2.5 mg/dl (male), Child-Pugh grade C) 5) Severe gastrointestinal dysfunction 6) Patient administrated drugs with the same indications of test drug or comparative drug, insulin GLP-1 analog, or DPP4 inhibitor, or treated by 4 or more diabetes drug 7) Pregnant female, lactating female, or female with possibility or planning of pregnancy 9) Patients evaluated incompetent by doctors in attendance
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Difference between 2 groups' amount of 60 minutes postprandial plasma active GLP-1 change after 2 weeks administration of test drug or comparative drug from baseline
- Secondary Outcome Measures
Name Time Method Difference of 60 minutes postprandial plasma active GLP-1 change between before and after 2 weeks administration of test drug or comparative drug and difference between 2 groups' of glycoalbmin, 60 minutes postprandial insulin, glucose, HOMA-R, HOMA-beta, and frequency of stool